Cingulate Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Cingulate Inc. (CING) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.43 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $592.82K, a 50.55% increase year-over-year.
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $90.72K, a 64.33% decline year-over-year.
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $357.65K, a 117.32% increase year-over-year.
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $393.77K, a 66.67% increase year-over-year.
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.43M, a 43.37% increase from fiscal 2024.
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $995.47K, a 22.49% increase from fiscal 2023.
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $812.67K, a 1.48% increase from fiscal 2022.
- Cingulate Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $800.80K, a 1726.84% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.43M 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $592.82K 10-Q · filed 2025-11-13 | $683.54K derived: sum of 2 quarters · filed 2026-08-13 | $1.04M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $90.72K 10-Q · filed 2026-08-13 | $448.37K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $357.65K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $995.47K 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $393.77K 10-Q · filed 2025-11-13 | $648.10K derived: sum of 2 quarters · filed 2025-11-13 | $812.68K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $254.33K 10-Q · filed 2025-11-13 | $418.91K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $164.57K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $812.67K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $236.25K 10-Q · filed 2024-11-07 | $453.63K derived: sum of 2 quarters · filed 2024-11-07 | $658.11K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $217.38K 10-Q · filed 2024-11-07 | $421.86K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $204.48K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $800.80K 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $205.66K 10-Q · filed 2023-11-13 | $412.84K derived: sum of 2 quarters · filed 2023-11-13 | $594.36K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $207.19K 10-Q · filed 2023-11-13 | $388.70K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $181.52K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $43.84K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |